Roche Holding AG (RHHVF)
237.72
-3.79
(-1.57%)
USD |
OTCM |
Apr 25, 16:00
Roche Price to Book Value: 5.430 for April 25, 2024
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| April 25, 2024 | 5.430 |
| April 24, 2024 | 5.517 |
| April 23, 2024 | 5.729 |
| April 22, 2024 | 5.601 |
| April 19, 2024 | 5.573 |
| April 18, 2024 | 5.484 |
| April 17, 2024 | 5.542 |
| April 16, 2024 | 5.562 |
| April 15, 2024 | 5.585 |
| April 12, 2024 | 5.594 |
| April 11, 2024 | 5.649 |
| April 10, 2024 | 5.610 |
| April 09, 2024 | 5.587 |
| April 08, 2024 | 5.534 |
| April 05, 2024 | 5.540 |
| April 04, 2024 | 5.633 |
| April 03, 2024 | 5.716 |
| April 02, 2024 | 5.711 |
| April 01, 2024 | 5.766 |
| March 28, 2024 | 5.851 |
| March 27, 2024 | 5.766 |
| March 26, 2024 | 5.715 |
| March 25, 2024 | 5.778 |
| March 22, 2024 | 5.730 |
| March 21, 2024 | 5.740 |
| Date | Value |
|---|---|
| March 20, 2024 | 5.940 |
| March 19, 2024 | 5.918 |
| March 18, 2024 | 5.886 |
| March 15, 2024 | 5.994 |
| March 14, 2024 | 6.035 |
| March 13, 2024 | 6.220 |
| March 12, 2024 | 6.382 |
| March 11, 2024 | 6.232 |
| March 08, 2024 | 6.194 |
| March 07, 2024 | 6.129 |
| March 06, 2024 | 6.126 |
| March 05, 2024 | 6.090 |
| March 04, 2024 | 5.988 |
| March 01, 2024 | 5.996 |
| February 29, 2024 | 5.951 |
| February 28, 2024 | 6.011 |
| February 27, 2024 | 6.031 |
| February 26, 2024 | 5.871 |
| February 23, 2024 | 6.035 |
| February 22, 2024 | 5.907 |
| February 21, 2024 | 6.002 |
| February 20, 2024 | 5.935 |
| February 16, 2024 | 5.826 |
| February 15, 2024 | 5.918 |
| February 14, 2024 | 5.777 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
5.430
Minimum
Apr 25 2024
12.70
Maximum
Apr 11 2022
8.478
Average
8.342
Median
Jan 09 2023
Price to Book Value Benchmarks
| AC Immune SA | 1.184 |
| CRISPR Therapeutics AG | 2.422 |
| Addex Therapeutics Ltd | 12.08 |
| NLS Pharmaceutics Ltd | -- |
Price to Book Value Related Metrics
| PE Ratio | 14.85 |
| PS Ratio | 2.822 |
| Price to Free Cash Flow | 14.91 |
| Price | 237.72 |
| Earnings Yield | 6.73% |
| Market Cap | 189.52B |
| Operating PE Ratio | 11.10 |
| Normalized PE Ratio | 14.68 |